<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Inherited susceptibility to melanoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Inherited susceptibility to melanoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Inherited susceptibility to melanoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hensin Tsao, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shelley R McCormick, MS, LCGC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The etiology of all cancers depends upon the interplay between environmental and genetic factors.</p><p>For melanoma, the most significant environmental risk factor is solar ultraviolet (UV) radiation exposure [<a href="#rid1">1</a>]. However, this risk is greatly influenced by genetic factors. As an example, skin type, a heritable trait, modifies the risk presented by a given amount of solar exposure. Dark-skinned populations have a much lower incidence of melanoma than fairer skinned populations exposed to equivalent sunlight. In the United States, the risk for melanoma in the White population is approximately 20 times higher than in the Black population [<a href="#rid2">2</a>].</p><p>However, there are other inherited factors, aside from those that define pigmentation, that contribute to hereditary risk. A study of familial risk and hereditability identified 23,980 people who had cancer and were twins [<a href="#rid3">3</a>]. The risk of concordance for melanoma was much greater than in the general population, and the increase was more pronounced in monozygotic compared with dizygotic twins. From this data, the heritability (ie, the proportion of variation of risk that can be attributed to genetic variation) of melanoma was estimated to be 58 percent.</p><p>Significant progress has been made toward understanding the genes that contribute to inherited susceptibility for melanoma in some patients [<a href="#rid4">4</a>]. Uncommon but high-risk alleles contribute to the hereditary cancer phenotype that includes multiple cases of the associated cancer or cancers on one side of the family, multiple primary cancers in a given individual, and early age of onset for a given cancer. With advances in genomic technologies and the conceptual framework to isolate more prevalent but lower risk alleles, the spectrum of genetic variants that contribute to melanoma risk has expanded.</p><p>The hereditary risk factors for melanoma are discussed here, along with potential implications for genetic screening. Other risk factors associated with the development of melanoma are discussed separately. (See  <a class="medical medical_review" href="/d/html/4844.html" rel="external">"Melanoma: Epidemiology and risk factors"</a>.)</p><p class="headingAnchor" id="H3663025564"><span class="h1">HEREDITARY VERSUS SPORADIC MELANOMA</span><span class="headingEndMark"> — </span>Melanomas can be divided into those that are sporadic and those with a hereditary component. Sporadic melanomas are due to random acquired pathogenic variants in melanocytes. Acquired pathogenic variants may be due to the environment, aging, chance events, other nonheritable factors, or possibly low-penetrance-risk single-nucleotide polymorphisms that specify risk traits (eg, skin color).</p><p>An estimated 8 to 12 percent of patients with melanoma have a family history of the disease. However, not all of these individuals have hereditary melanoma [<a href="#rid5">5,6</a>]. In some cases, the apparent familial inheritance pattern may be due to clustering of sporadic cases in families with common heavy sun exposure and a susceptible skin type. In other situations, co-inheritance of modifying genes may enhance or inhibit the apparent penetrance of a high-risk pathogenic variant and thus dictate the strength of the family history.</p><p>In areas of moderate to high incidence of melanoma, families with three relatives with melanoma, individuals with three or more primary melanomas, or individuals with melanoma diagnosed at an earlier age (before age 40) are candidates for hereditary melanoma susceptibility testing [<a href="#rid7">7,8</a>]. Twenty to 60 percent of these families harbor a pathogenic variant in <em>CDKN2A</em>/p16 [<a href="#rid7">7,9-11</a>]. </p><p>Less common melanoma susceptibly genes include <em>CDKN2A</em>/<em>ARF</em>, <em>CDK4</em>, <em>TERT</em>, <em>MITF</em>, <em>BAP1</em>, and <em>POT1</em>. Other genes that may soon be included in hereditary melanoma testing include <em>ACD</em>, <em>MC1R</em>, <em>RB1</em>, and <em>TERF2IP</em> [<a href="#rid11">11,12</a>].</p><p>In addition, there are other cancer predisposition syndromes in which melanoma is part of a broader spectrum of tumors but is not the most common malignancy. An example of this is <em>BRCA</em>-associated hereditary breast and ovarian cancer. In this condition, the primary risks are for breast and ovarian cancers, but the risks of some other malignancies are also increased, including melanoma. </p><p>These cancer predisposition syndromes may be classified into those in which melanoma is the most frequent manifestation and those in which melanoma is less common than other tumor types [<a href="#rid11">11</a>]. The following section discusses the genes associated with syndromes where melanoma is the dominant feature.</p><p class="headingAnchor" id="H3148538106"><span class="h1">HIGH-RISK SUSCEPTIBILITY LOCI ASSOCIATED WITH HEREDITARY MELANOMA</span><span class="headingEndMark"> — </span>Melanoma is the most common malignancy associated with the genes discussed in this section. Other types of tumors may also be seen but are less frequent [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H3"><span class="h2">CDKN2A gene</span><span class="headingEndMark"> — </span><em>CDKN2A</em> is the most frequently identified pathogenic variant in familial forms of melanoma. Pathogenic variants in the <em>CDKN2A</em> and <em>CDK4</em> (refer below) genes can be found in a subset of families with familial atypical multiple mole melanoma syndrome (FAMMM). </p><p class="headingAnchor" id="H2521117160"><span class="h3">Pathogenesis</span><span class="headingEndMark"> — </span>Initial clues that chromosome 9p21 contained a melanoma susceptibility locus came from cytogenetic investigations and studies of loss of heterozygosity (LOH) [<a href="#rid13">13</a>]. Strong evidence for linkage to this region came from an analysis of 11 melanoma pedigrees in Texas and Utah [<a href="#rid14">14</a>]. Subsequent studies using positional cloning methods isolated a candidate locus that was ultimately designated <em>CDKN2A</em> [<a href="#rid15">15,16</a>]. This gene has also been called <em>MTS1</em>, <em>p16INK4A</em>, and <em>CDKN2</em>. The gene encodes two proteins, p16 and p14ARF, that are transcribed in alternate reading frames through the use of alternative first exons [<a href="#rid17">17</a>]. Germline <em>CDKN2A</em> pathogenic variants in melanoma families are usually missense or nonsense changes that impair the function of p16, although rare pathogenic variants in <em>p14ARF</em> have also been reported [<a href="#rid9">9,10,18</a>]. </p><p>The p16 protein is a negative regulator of cell cycle progression at the G1/S checkpoint [<a href="#rid19">19,20</a>]. It interacts with the cyclin-dependent kinases (CDKs; CDK4 or CDK6), enzymes that control early events in the cell cycle, to catalyze phosphorylation of the retinoblastoma family of proteins. A complex of cyclin D and CDK together phosphorylate the retinoblastoma gene protein (RB1), thereby releasing the transcription factor E2F1 from RB1 and allowing E2F1 to induce S phase genes. Consequently, the cell proceeds from G1 arrest through S phase. The p16 protein binds to and inhibits CDK4, and thus serves as a brake on cell cycle progression. </p><p>Inactivating pathogenic variants of p16 disrupt its inhibitory function on CDK4, thereby permitting inappropriate progression through the cell cycle [<a href="#rid21">21</a>]. Tumorigenesis may result from an impairment in senescence, cell differentiation, or cell death [<a href="#rid22">22,23</a>]. (See <a class="local">'CDK4 gene'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h3">Prevalence of pathogenic variants</span><span class="headingEndMark"> — </span>The frequency of germline <em>CDKN2A</em> pathogenic variants in patients with hereditary melanoma is highly variable. </p><p>The most extensive analysis of melanoma families found that the major features associated with an increased frequency of germline <em>CDKN2A</em> pathogenic variants were multiple cases of melanoma in a family, early age at diagnosis, and family members with multiple primary melanomas or pancreatic cancer [<a href="#rid10">10</a>]. Using these criteria, 385 families with three or more patients with melanoma from the Melanoma Genetics Consortium (GenoMEL) were compared across various geographical locales. Overall, 39 percent of these selected families had <em>CDKN2A</em> pathogenic variants, ranging from 20 percent (32 of 162) in Australia to 45 percent (29 of 65) in North America to 57 percent (89 of 157) in Europe. The presence of pancreatic cancer in a given family also predicted <em>CDKN2A</em> pathogenic variants, except for in Australian families.</p><p>The prevalence of germline <em>CDKN2A</em> pathogenic variants in the general population with melanoma is much lower than in studies of multiple-case families, which may reflect the presence of other co-inherited risk alleles, increased detection bias, or unknown confounders in these cohorts. This was illustrated by a study of 3550 patients with melanoma in which 65 <em>CDKN2A</em> pathogenic variant carriers were identified (1.8 percent) [<a href="#rid24">24</a>]; the rates of <em>CDKN2A</em> pathogenic variants among individuals with a single primary melanoma and multiple primary melanomas were 1.2 and 2.9 percent, respectively [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Pathogenic variant penetrance</span><span class="headingEndMark"> — </span>Estimates of the penetrance of <em>CDKN2A</em> pathogenic variants among carriers vary depending upon the methods of population ascertainment [<a href="#rid24">24,26</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In the multicenter Genes Environment and Melanoma (GEM) study, histories were obtained from 429 first-degree relatives of index cases, seeking cases of melanoma [<a href="#rid24">24</a>]. In these individuals, the incidence of melanoma in <em>CDKN2A</em> carriers was estimated to be 14, 24, and 28 percent at 50, 70, and 80 years of age, respectively. This compared to an incidence of melanoma of 1.5, 4.5, and 6.2 percent in the relatives of non-<em>CDKN2A</em> carriers and an estimated 0.6, 1.6, and 2.6 percent in the baseline population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the GenoMEL study, which was based upon 80 families with documented <em>CDKN2A</em> pathogenic variants and multiple affected family members, the incidence of melanoma was 30 percent by age 50 years and 67 percent by age 80 years [<a href="#rid26">26</a>]. The higher penetrance observed in this study at least in part reflects the bias induced by only analyzing families with two or more cases. An interaction between genetic predisposition and environmental factors was suggested in this series by geographic variations. In Europe, the United States, and Australia, penetrance at age 80 years was 58, 76, and 91 percent, respectively.</p><p></p><p>The same factors that influence the incidence of melanoma in the general population (eg, total nevus count, presence of dysplastic nevi, sunburn) also affect <em>CDKN2A</em> penetrance. This was illustrated in a study of 53 melanoma-prone families and 295 families ascertained through probands diagnosed with melanoma but unselected for family history [<a href="#rid27">27</a>]. The presence of both sunburn and a melanoma predisposing gene increased the risk of melanoma 15 times more than in noncarriers. In families with <em>CDKN2A</em> pathogenic variants, total nevus count, dysplastic nevi, and sunburn all significantly increased the risk of developing melanoma. In addition, the presence of variants in the <em>MC1R</em> gene increases the risk of developing melanoma in <em>CDKN2A</em> carriers. (See <a class="local">'Melanocortin-1 receptor'</a> below and  <a class="medical medical_review" href="/d/html/4844.html" rel="external">"Melanoma: Epidemiology and risk factors"</a>.)</p><p>The generalizability of these observations to other geographic areas is uncertain since most of the mutated <em>CDKN2A</em> genes were derived from a single founder pathogenic variant. These observations require confirmation.</p><p class="headingAnchor" id="H11"><span class="h2">CDK4 gene</span><span class="headingEndMark"> — </span>p16 inhibits both CDK4 and CDK6, thereby regulating cell cycle progression. Several melanoma families have been described who lack pathogenic variants in <em>CDKN2A</em> but have germline pathogenic variants in the <em>CDK4</em> gene [<a href="#rid28">28-30</a>]. In these families, the alterations were on arginine 24 of <em>CDK4</em>, resulting in a CDK4 protein that was insensitive to inhibition by p16. There are no apparent differences in the phenotype (eg, age at diagnosis, number of melanomas) of families carrying either <em>CDKN2A</em> or <em>CDK4</em> pathogenic variants [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H546103950"><span class="h2">Shelterin complex genes</span><span class="headingEndMark"> — </span>The shelterin complex protects chromosomal ends by regulating how the telomerase complex interacts with telomeres [<a href="#rid32">32</a>]. This complex includes multiple genes, three of which have been associated with familial melanoma:</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>POT1</em></strong><strong> </strong>– <em>POT1</em> controls telomerase-mediated telomere elongation and is part of the shelterin complex. Four percent of familial melanoma pedigrees negative for <em>CDKN2A</em> and <em>CDK4</em> pathogenic variants were found to have a variant in <em>POT1</em>. Two of 34 (5.8 percent) families with five or more melanoma cases carried a <em>POT1</em> variant [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>ACD</em></strong><strong> </strong>and<strong> </strong><strong><em>TERF2IP</em></strong> –<strong> </strong>Following the reports of <em>POT1</em> involvement in familial melanoma, five other proteins involved in the shelterin complex (ACD, TERF2IP, TERF1, TERF2, TINF2) were studied [<a href="#rid32">32</a>]. Six melanoma families had pathogenic variants in the <em>ACD </em>gene. There were five distinct pathogenic variants in <em>ACD</em>, and four of those were in the <em>POT1</em> binding domain. Four families carried <em>TERF2IP</em> variants. Novel alterations were identified in <em>TERF1</em>, <em>TERF2</em>, and <em>TINF2</em>; however, they were not significantly associated with melanoma.</p><p></p><p>Certain alterations in <em>POT1</em>, <em>ACD</em>, and <em>TERF21P</em> have also been associated with hereditary chronic lymphocytic leukemia and familial glioma [<a href="#rid34">34,35</a>]</p><p class="headingAnchor" id="H845755851"><span class="h2">TERT</span><span class="headingEndMark"> — </span>A promoter mutation in <em>TERT</em> (c.-57T&gt;G) has been identified in two unrelated families with multiple cases of melanoma. The <em>TERT</em> promoter mutation was first identified in a German family with 14 cases of melanoma [<a href="#rid36">36</a>]. A United Kingdom family with the same promoter mutation had seven cases of melanoma [<a href="#rid37">37</a>]. Both families had carriers with bladder cancer. Although rare, the <em>TERT</em> promoter mutation appears to be associated with a high risk for early onset melanoma and possibly other cancers. Variants in the promoter region are thought to increase recognition sites for Ets/Tcf transcription factors and enhance <em>TERT</em> expression [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H616737933"><span class="h2">BAP1 gene</span><span class="headingEndMark"> — </span>Germline variants in the <em>BRCA1</em>-associated protein 1 (<em>BAP1</em>)<em> </em>gene are linked to the BAP1-tumor predisposition syndrome (BAP1-TPDS). <em>BAP1 </em>encodes a deubiquitinating enzyme, which functions as a tumor suppressor.</p><p>Germline pathogenic variants in the <em>BAP1</em> gene have been identified in families with cutaneous and uveal melanoma [<a href="#rid38">38,39</a>]. In an Australian cutaneous melanoma registry, <em>BAP1</em> variants were identified in 7 of 1109 cases (0.6 percent). The prevalence in other populations has yet to be determined [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/d/html/16540.html" rel="external">"The molecular biology of melanoma", section on 'Mutations with prognostic relevance'</a>.)</p><p>In addition to cutaneous and ocular melanoma, mesothelioma (both pleural and peritoneal) and renal cancer have been observed in <em>BAP1</em> families and are proposed to be part of the core tumor spectrum linked to germline <em>BAP1</em> pathogenic variants; furthermore, somatic <em>BAP1 </em>pathogenic variants have been described in renal cell carcinoma [<a href="#rid38">38,39,41,42</a>]. (See  <a class="medical medical_review" href="/d/html/2504.html" rel="external">"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging"</a> and  <a class="medical medical_review" href="/d/html/2982.html" rel="external">"Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'BAP1 gene'</a> and  <a class="medical medical_review" href="/d/html/2948.html" rel="external">"Hereditary kidney cancer syndromes", section on 'Hereditary BAP-1-associated renal cell carcinoma'</a>.)</p><p>The presence of unique highly atypical nevoid melanoma-like melanocytic proliferations has also been observed in some individuals with <em>BAP1</em> pathogenic variants [<a href="#rid38">38</a>]. <em>BAP1</em>-absent dermal lesions called melanocytic <em>BAP1</em>-mutated atypical intradermal tumors (MBAITs) can be found adjacent to these lesions [<a href="#rid43">43</a>]. The lesions may be the most common feature in <em>BAP1</em> pathogenic variant carriers, identified in 75 percent of <em>BAP1</em> carriers who underwent total body skin examinations in one study [<a href="#rid44">44</a>]. Prior to the description of MBAITs, these lesions were likely diagnosed as atypical Spitz tumors. (See  <a class="medical medical_review" href="/d/html/13523.html" rel="external">"Spitz nevus and atypical Spitz tumors"</a>.)</p><p>Other tumor types may be part of the BAP1-TPDS spectrum, including basal cell carcinoma, meningioma, and cholangiocarcinoma [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H2899853108"><span class="h1">MODERATE RISK POLYMORPHISMS ASSOCIATED WITH SPORADIC MELANOMA</span></p><p class="headingAnchor" id="H3694784108"><span class="h2">MITF (E318K) variant</span><span class="headingEndMark"> — </span>A rare germline missense mutation in the microphthalmia-associated transcription factor (<em>MITF</em>) gene, E318K, confers a 2.2- to 4.8-fold increased risk of melanoma. The E318K variant is thought to enable <em>MITF</em> to act as an oncogene by abolishing a sumoylation site, thereby altering the transcriptional function of the MITF protein [<a href="#rid46">46-48</a>]. </p><p>The prevalence (carrier frequency) of the <em>MITF</em> E318K variant in patients with personal histories of melanoma has been reported to be 0.017 in an Australian/United Kingdom population [<a href="#rid46">46</a>], 0.014 in a French population [<a href="#rid47">47</a>], and 0.009 in an Italian population [<a href="#rid49">49</a>]. The <em>MITF</em> E318K variant was identified in 1.9 percent of all <em>p16INK4A</em> wild-type melanoma patients in a Spanish cohort. The prevalence of <em>MITF</em> increased to 2.6 percent in those with multiple primary melanomas [<a href="#rid50">50</a>]. In an Italian cohort, carriers had a threefold higher risk of melanoma compared with controls and a 6.4-fold higher risk for multiple primary melanomas [<a href="#rid49">49</a>].</p><p>Some studies have identified a relationship of this variant with renal cell carcinoma, pancreatic cancer, and pheochromocytoma/paraganglioma [<a href="#rid48">48,50,51</a>]. However, it is not yet clear whether the association between this variant and other malignancies is indeed related to the <em>MITF</em> E318K variant or a result of shared environmental or polygenic risk factors. (See  <a class="medical medical_review" href="/d/html/2982.html" rel="external">"Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Translocation renal cell carcinoma (MiT/TFE-related RCC)'</a> and  <a class="medical medical_review" href="/d/html/133.html" rel="external">"Pheochromocytoma in genetic disorders"</a> and  <a class="medical medical_review" href="/d/html/5231.html" rel="external">"Paragangliomas: Epidemiology, clinical presentation, diagnosis, and histology"</a>.)</p><p>A meta-analysis of data compiled from nine published studies, which were conducted on a mixture of hereditary and sporadic melanoma populations, demonstrated that <em>MITF</em> E318K was significantly correlated with melanoma. Additionally, this study systematically evaluated the prevalence of the <em>MITF</em> E318K variant in multiple cancer cohorts using germline whole-exome sequence data from the TCGA panel and from several genetically-enriched cohorts. Among the 25 cancers tested (including renal cell cancer, pancreatic cancer, and pheochromocytoma/paraganglioma), uterine carcinosarcoma and melanoma demonstrated the strongest associations with the <em>MITF</em> E318K variant [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H1923834763"><span class="h2">Melanocortin-1 receptor</span><span class="headingEndMark"> — </span>Variants of the <em>MC1R</em> gene have been associated with the red hair/fair skin phenotype [<a href="#rid53">53</a>], which is more common in subjects with cutaneous melanoma. In addition, analysis of the <em>MC1R</em> gene in patients with melanoma has shown an increased prevalence of <em>MC1R</em> gene variants compared with healthy controls [<a href="#rid54">54-60</a>].</p><p>This was illustrated by a study in which the <em>MC1R</em> gene was sequenced in 267 patients with melanoma and 382 control subjects [<a href="#rid54">54</a>]. The presence of <em>MC1R</em> variants was associated with a two- to fourfold increase in the risk of melanoma compared with individuals carrying the wild-type <em>MC1R</em> gene. The association between <em>MC1R</em> variants and melanoma was stronger in individuals with fewer additional risk factors (eg, those with dark skin or few nevi). In addition, patients with a variant <em>MC1R</em> gene were three- to fourfold more likely to have thick melanomas.</p><p>There also is evidence that variants of <em>MC1R</em> can interact with other genes involved in the pathogenesis of melanoma. <em>MC1R</em> variants increase the penetrance of <em>CDKN2A</em> [<a href="#rid61">61</a>]. In a Melanoma Genetics Consortium (GenoMEL) study of 815 <em>CDKN2A</em> pathogenic variant carriers from 186 families, the presence of one of the four most common <em>MC1R</em> variants was associated with a statistically significant increased risk of melanoma; the presence of two or more variants further increased that risk compared with having just one variant (odds ratios compared with those without an <em>MC1R</em> variant were 5.8 and 2.3, respectively).</p><p>The <em>BRAF</em> oncogene is the most common site for somatic pathogenic variants in melanoma [<a href="#rid62">62</a>]. Such molecular alterations are more common in melanomas arising in skin that has little chronic sun-induced damage, and they are less frequent in melanomas associated with severe, chronic solar damage [<a href="#rid63">63</a>]. In patients with melanoma originating in skin with limited sun-induced damage, somatic <em>BRAF</em> mutations are strongly associated with the presence of inherited <em>MC1R</em> variants and are less common in patients with wild-type <em>MC1R</em> [<a href="#rid64">64,65</a>].</p><p class="headingAnchor" id="H3589942854"><span class="h1">TUMOR SYNDROMES WITH INCREASED MELANOMA RISK</span><span class="headingEndMark"> — </span>Although melanoma is not the most common malignancy associated with the genes discussed in this section, the risk for melanoma in patients with these genetic alterations remains elevated compared with the general population [<a href="#rid11">11</a>]. </p><p class="headingAnchor" id="H14"><span class="h2">BRCA1 and BRCA2 genes</span><span class="headingEndMark"> — </span>The <em>BRCA1</em> and<em> BRCA2</em> genes encode proteins that are important in DNA repair. Germline pathogenic variants are associated primarily with an increased risk of breast, ovarian, and prostate cancers; however, other cancer types have been associated with pathogenic variants. (See  <a class="medical medical_review" href="/d/html/758.html" rel="external">"Cancer risks and management of BRCA1/2 carriers without cancer"</a>.) </p><p>An association of <em>BRCA1</em> and<em> BRCA2</em> pathogenic variants with melanoma has been observed in some but not all studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a report from the Breast Cancer Linkage Consortium (BCLC), <em>BRCA2</em> carriers had an increased risk of cutaneous melanoma (relative risk 2.6) [<a href="#rid66">66</a>]. <em>BRCA2</em> pathogenic variants also appear to occur in families with aggregations of ocular melanoma (7 of 62 such families in one series) [<a href="#rid67">67</a>]. Another large single-institution study examined cancer risk in 993 <em>BRCA1</em> and <em>BRCA2</em> carriers; within the <em>BRCA1</em> cohort, there was a trend toward an increased risk for melanoma [<a href="#rid68">68</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other studies have not found an association between melanoma and inherited pathogenic variants in <em>BRCA1</em> and <em>BRCA2</em>. A study of individuals with cutaneous melanoma and Ashkenazi Jewish ancestry detected no germline pathogenic variants in the 92 individuals analyzed for the three <em>BRCA</em> Ashkenazi Jewish founder mutations [<a href="#rid69">69</a>]. With respect to ocular melanoma, no germline pathogenic variants in <em>BRCA1</em> or <em>BRCA2</em> were detected in a cohort of 25 individuals with a personal history of ocular melanoma and a personal/family history of breast or ovarian cancers [<a href="#rid70">70</a>].</p><p></p><p class="headingAnchor" id="H4186371573"><span class="h2">TP53</span><span class="headingEndMark"> — </span>Germline pathogenic variants in <em>TP53</em> are associated with Li-Fraumeni syndrome. Li-Fraumeni syndrome is characterized by early onset and multiple primary cancers, particularly sarcomas, breast cancers, adrenocortical carcinomas, brain tumors, and leukemias. Increased rates of melanomas have also been reported [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/d/html/14255.html" rel="external">"Li-Fraumeni syndrome"</a>.)</p><p class="headingAnchor" id="H861010372"><span class="h2">PTEN gene</span><span class="headingEndMark"> — </span>Cowden syndrome, due to pathogenic variants in the <em>PTEN</em> gene, is classically associated with an increased risk for cancer of the breast, colon, endometrium, and thyroid, as well as benign hamartomas. Individuals with Cowden syndrome often have macrocephaly, autism spectrum disorders, and specific skin lesions, such as trichilemmomas and papillomatous papules. <em>PTEN</em> carriers may also have an increased risk for melanoma [<a href="#rid72">72,73</a>]. (See  <a class="medical medical_review" href="/d/html/16543.html" rel="external">"PTEN hamartoma tumor syndromes, including Cowden syndrome"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">RB1 gene</span><span class="headingEndMark"> — </span>The cyclin D/cyclin-dependent kinase (CDK) complex phosphorylates the RB1 protein, allowing cell cycle progression from G1 to S phase; p16 binds to and inhibits the activities of these three enzymes, functioning as a brake on cell cycle progression. (See <a class="local">'Pathogenesis'</a> above.) </p><p>In one large cohort study of retinoblastoma survivors, the mortality from second cancers, including melanoma, was significantly increased [<a href="#rid74">74</a>]. Although germline <em>RB1</em> pathogenic variants have not been reported in patients with melanoma, alterations or loss of <em>RB1</em> expression has been described in a limited number of melanoma cell lines [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H1386298341"><span class="h1">GENETIC TESTING</span></p><p class="headingAnchor" id="H2312206772"><span class="h2">Who to test</span><span class="headingEndMark"> — </span>Four clinical scenarios may warrant genetic counseling and/or testing for hereditary melanoma:</p><p class="bulletIndent1"><span class="glyph">●</span>Melanoma diagnosed at earlier than expected ages</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple relatives with melanoma</p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with multiple primary melanomas</p><p class="bulletIndent1"><span class="glyph">●</span>Other types of cancer in the family</p><p></p><p>The general principles of genetic testing are discussed separately. (See  <a class="medical medical_review" href="/d/html/2901.html" rel="external">"Genetic testing"</a>.)</p><p class="headingAnchor" id="H3846655101"><span class="h3">Early onset melanoma</span><span class="headingEndMark"> — </span>Earlier than expected age at diagnosis is associated with an increased risk for a hereditary melanoma syndrome. The average age of onset for melanoma in the United States population is 64 years (Surveillance, Epidemiology, and End Results [SEER]), while the average age of onset in families with mutated <em>CDKN2A</em> (the most common pathogenic variant) is 35 years (range 14 to 68 years) [<a href="#rid7">7,26</a>]. However, early onset alone is not necessarily predictive of germline predisposing pathogenic variants, and only a small percentage of patients with early onset melanoma will actually have a <em>CDKN2A</em> pathogenic variant. (See <a class="local">'CDKN2A gene'</a> above.)</p><p>It is also important to note that unlike other hereditary cancer predisposition conditions, standalone early onset melanoma may not be associated with genetic susceptibility. In one cohort of young patients with a personal history of melanoma (median age 32 years) and no family history of melanoma, there was only one patient with a germline <em>CDKN2A</em> pathogenic variant [<a href="#rid76">76</a>]. In another study, a deleterious <em>CDKN2A</em> pathogenic variant was identified in only 1 of 60 patients diagnosed with melanoma prior to age 20 years, and that patient was part of a kindred with a known <em>CDKN2A</em> pathogenic variant [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H3223391780"><span class="h3">Significant family history of melanoma</span><span class="headingEndMark"> — </span>Multiple cases of melanoma in a family may suggest that a germline pathogenic variant in the family is playing a role in the cancer development. In the international Melanoma Genetics Consortium (GenoMEL) study, the likelihood of finding a pathogenic variant in the <em>CDKN2A</em> gene increased progressively with the number of involved family members and was approximately 70 percent when six or more members of the kindred had cutaneous melanoma [<a href="#rid10">10</a>].</p><p>The criteria that constitute a "significant" family history of melanoma depend in part on the geographic location of the families. Sun exposure is a proven modifier of melanoma risk. Therefore, in areas where there is a high incidence of melanoma, at least three family members would need to be affected to suggest hereditary susceptibility. However, in areas of low melanoma incidence, two affected family members may be sufficient to warrant a referral for genetic counseling and/or testing [<a href="#rid11">11</a>]. </p><p>Relatedness of the affected family members is also critical in estimating the probably of genetic alterations. For instance, a mother, daughter, and son trio of affected patients is more likely due to shared genetic content than a mother, niece, and distant cousin. </p><p>MelaPRO is software program that utilizes best-estimate penetrance along with Mendelian laws of inheritance to arrive at a <em>CDKN2A</em> carrier probability, with separate modules for different geographic areas [<a href="#rid78">78</a>]. MelaPRO is included in CancerGene, a free downloadable software program.</p><p class="headingAnchor" id="H2066597250"><span class="h3">Multiple primary melanomas</span><span class="headingEndMark"> — </span>Another feature of inherited cancer predisposition is the development of multiple primary cancers, and this appears to be true in hereditary melanoma. </p><p>Data on the incidence of germline <em>CDKN2A</em> pathogenic variants in individual patients with multiple primary melanomas are variable. In the Genes Environment and Melanoma (GEM) cohort, 2.9 percent of 1189 patients with multiple primary melanomas had germline <em>CDKN2A</em> pathogenic variants [<a href="#rid24">24</a>]. In several smaller studies, the incidence of pathogenic variants in patients with multiple melanomas ranged between 8 and 16 percent [<a href="#rid79">79-82</a>].</p><p>In families with multiple members with melanoma, the likelihood of identifying a <em>CDKN2A</em> pathogenic variant is much higher with increasing numbers of individuals with multiple primary melanomas. In an international study of 385 melanoma families, 70 percent of families had a <em>CDKN2A</em> pathogenic variant when there were three or more relatives with multiple primary melanomas. In contrast, the detection rate was &lt;20 percent in families without individuals with multiple primary melanomas [<a href="#rid10">10</a>]. </p><p class="headingAnchor" id="H4045693138"><span class="h3">Familial melanoma and other malignancies</span><span class="headingEndMark"> — </span>The occurrence of other associated tumors (eg, pancreatic cancer, breast cancer, brain tumors), either in the patient's personal history or family history, should be taken into account when considering possible hereditary predisposition syndromes. </p><p>Melanoma and pancreatic cancer have both been associated with pathogenic variants in the <em>CDKN2A</em> gene [<a href="#rid29">29,83-85</a>]. The relationship between <em>CDKN2A</em> pathogenic variants and other cancer types is illustrated by a study based upon 330 high-risk melanoma-prone families that included 236 patients with sporadic multiple primary melanoma and 466 cases with familial melanoma [<a href="#rid86">86</a>]. Pathogenic variants in <em>CDKN2A</em> were identified in 66 families. There was a statistically significant increased incidence of other solid tumors compared with those families with wild-type <em>CDKN2A</em> (prevalence ratio 3.0). Specific tumor types for which there was an increased incidence included pancreatic cancer, lung cancer, and breast cancer (prevalence ratios 3.0, 3.0, and 2.0, respectively). Similar associations have been observed in families with alterations in <em>CDK4</em> [<a href="#rid7">7,31</a>]. </p><p>Specific pathogenic variants in the <em>CDKN2A</em> gene may have other associations:</p><p class="bulletIndent1"><span class="glyph">●</span>Brain tumors have been described in some melanoma-prone kindreds [<a href="#rid87">87</a>] with germline alterations of the p14ARF component of <em>CDKN2A</em> [<a href="#rid88">88</a>]. An exon 1 beta splice junction mutational hotspot in p14ARF has been reported [<a href="#rid89">89</a>]; the contribution of these changes to the full spectrum of hereditary melanoma remains to be clarified.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A <em>CDKN2A</em> missense variant (rs3731249) confers a threefold increased risk for acute lymphoblastic leukemia in children of European (odds ratio 3.0) and Hispanic ancestry (odds ratio 2.8). The variant was not significantly associated with other cancers, suggesting that this variant is specific to acute lymphoblastic leukemia risk [<a href="#rid90">90</a>].</p><p></p><p>Pathogenic variants that have been associated with various other malignancies include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BAP1</em></strong> – In addition to cutaneous and ocular melanoma, other cancers, including non-asbestos-related mesothelioma and renal cancer, have been reported in families with germline <em>BAP1</em> pathogenic variants [<a href="#rid38">38,39,41</a>]. The presence of unique nevoid melanomas and highly atypical nevoid melanoma-like melanocytic proliferations has also been observed in some of these individuals [<a href="#rid38">38</a>]. (See <a class="local">'BAP1 gene'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>MITF</em></strong> – The <em>MITF</em> E318K pathogenic variant is reported to be associated with melanoma, renal cell cancer, breast cancer, pancreatic cancer, and lymphoma [<a href="#rid11">11,47,49</a>]. (See <a class="local">'MITF (E318K) variant'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BRCA1</em></strong><strong> and </strong><strong><em>BRCA2</em></strong> – Molecular alterations in the <em>BRCA1</em> and <em>BRCA2</em> genes are most commonly associated with breast and ovarian cancers but can also be associated with melanoma and other malignancies. (See <a class="local">'BRCA1 and BRCA2 genes'</a> above and  <a class="medical medical_review" href="/d/html/758.html" rel="external">"Cancer risks and management of BRCA1/2 carriers without cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>PTEN</em></strong> – The <em>PTEN</em> gene is commonly associated with breast, uterine, and non-papillary thyroid cancer, along with other features such as macrocephaly. If these features are present in a family with melanoma, testing for pathogenic variants in the <em>PTEN</em> gene should be considered. (See <a class="local">'PTEN gene'</a> above and  <a class="medical medical_review" href="/d/html/16543.html" rel="external">"PTEN hamartoma tumor syndromes, including Cowden syndrome"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>TP53</em></strong> – Families with a history of melanoma and breast cancer along with sarcoma, brain cancer, and leukemia should be tested for pathogenic variants in <em>TP53</em>. (See <a class="local">'TP53'</a> above and  <a class="medical medical_review" href="/d/html/14255.html" rel="external">"Li-Fraumeni syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H3434691103"><span class="h2">Single-gene versus multigene panel</span><span class="headingEndMark"> — </span>The clinical availability of next-generation sequencing technology has led to the development of cancer gene panel testing, which simultaneously analyzes multiple cancer susceptibility genes. Commercially available multigene panel tests may be targeted to a specific type of cancer (eg, breast, colon) or may broadly test cancer genes (as so called "pan-cancer" panels). Melanoma-specific panels, offered by some clinical testing laboratories, typically include an analysis of<em> BAP1</em>, <em>BRCA2</em>, <em>CDK4</em>, <em>CDKN2A</em>, <em>MITF</em>, <em>POT1</em>, <em>PTEN</em>, <em>RB1</em>, and<em> TP53</em>. When the personal and/or family history indicates testing for more than one gene, multigene panel testing may be a more efficient method of testing. For example, a family history of melanoma, pancreatic cancer, and breast cancer may warrant both <em>CDKN2A</em> and <em>BRCA2</em> testing. Such approaches may also facilitate the identification of actionable pathogenic variants [<a href="#rid91">91</a>]. </p><p>Given the broad testing available, multigene panel testing may incidentally detect a melanoma susceptibility gene pathogenic variant in an individual or family not phenotypically suggestive of hereditary melanoma risk. Such testing should only be performed once patients are counseled appropriately and made aware of the possibility of incidental findings, the implications for relatives, the psychological consequences, and the potential changes to medical management. (See  <a class="medical medical_review" href="/d/html/2901.html" rel="external">"Genetic testing"</a>.)</p><p>Although single-gene <em>CDKN2A</em> testing is used less commonly in the age of multigene panels, the lessons learned from <em>CDKN2A</em> testing may be relevant for other melanoma susceptibility genes. The interpretation of such test results is difficult, especially in the context of a negative result. Importantly, unaffected individuals from hereditary melanoma families who test negative for the familial <em>CDKN2A</em> pathogenic variant are still at increased risk of developing melanoma despite their negative genetic status [<a href="#rid92">92</a>]. This leads to the concern that a negative test result will result in decreased surveillance and vigilance.</p><p>Genetic testing for <em>CDKN2A</em> pathogenic variants may increase the motivation for risk-reducing behaviors and frequent surveillance, as well as lower the biopsy threshold for suspicious lesions, which might lead to earlier diagnosis and improved survival [<a href="#rid93">93,94</a>]. On the other hand, genetic testing could potentially cause psychological distress, lead to unnecessary biopsies in carriers, and reduce the motivation for preventive behaviors in those without <em>CDKN2A</em> pathogenic variants [<a href="#rid95">95</a>]. (See  <a class="medical medical_review" href="/d/html/2901.html" rel="external">"Genetic testing"</a>.)</p><p>Genetic counseling, with or without genetic testing, may promote awareness in individuals at increased risk for melanoma and increase compliance with photoprotection recommendations in both unaffected carriers and unaffected noncarriers [<a href="#rid96">96</a>]. A study involving two <em>CDKN2A</em> families concluded that educating patients about genetic testing as well as photoprotection increased photoprotective behaviors, regardless of pathogenic variant status [<a href="#rid97">97</a>]. In addition, knowledge of familial melanoma risks in families who decline genetic testing has been suggested to encourage melanoma risk-reducing and early detection behaviors [<a href="#rid98">98</a>]. In another study, genetic test reporting contributed to the understanding of hereditary risk for melanoma regardless of carrier status [<a href="#rid99">99</a>]. (See  <a class="medical medical_review" href="/d/html/4842.html" rel="external">"Primary prevention of melanoma"</a>.)</p><p class="headingAnchor" id="H2548861030"><span class="h1">SURVEILLANCE AND MANAGEMENT</span><span class="headingEndMark"> — </span>Many of the melanoma-associated genes on multigene panels do not have a precisely defined risk for melanoma. The personal and family history should be used to make surveillance and management decisions. Referral to a high-risk specialist may be valuable in making decisions, particularly since there may be guidelines for management of other cancer risks (eg, breast, colon, or ovarian).</p><p class="headingAnchor" id="H3064280986"><span class="h2">Surveillance in melanoma-prone kindreds</span><span class="headingEndMark"> — </span>For patients within a melanoma-prone kindred, including those previously treated for melanoma, skin checks by a health care provider trained to detect melanoma are essential and should be performed at least annually. If there are a large number of clinically atypical moles, skin exams should be performed at least twice a year. Skin self-exams should be performed monthly, and individuals should be trained on the proper technique. Sun protective practices should also be engaged, including sun avoidance during midday and the use of sunscreen.</p><p>The approaches to screening and early detection of melanoma as well as preventative measures are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4845.html" rel="external">"Screening for melanoma in adults and adolescents"</a> and  <a class="medical medical_review" href="/d/html/4842.html" rel="external">"Primary prevention of melanoma"</a>.)</p><p>In families with a known or suspected <em>CDKN2A</em> pathogenic variant associated with a family history of pancreatic cancer, pathogenic variant carriers should undergo surveillance for melanoma because of the risk of developing melanoma. (See  <a class="medical medical_review" href="/d/html/4845.html" rel="external">"Screening for melanoma in adults and adolescents"</a> and  <a class="medical medical_review" href="/d/html/4842.html" rel="external">"Primary prevention of melanoma"</a>.)</p><p class="headingAnchor" id="H3621698741"><span class="h2">Surveillance for other cancers</span><span class="headingEndMark"> — </span>In families with a <em>CDKN2A</em> pathogenic variant or another molecular alterations known to be associated with hereditary melanoma, or suspected or known to be associated with a family history of pancreatic cancer, <em>CDKN2A</em> pathogenic variant carriers should also be referred to a gastroenterology specialist to discuss the option of pancreatic cancer surveillance. Although the efficacy of pancreatic cancer surveillance remains under investigation, the International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with an increased risk for familial pancreatic cancer recommends consideration of pancreatic cancer surveillance for individuals with <em>CDKN2A</em> pathogenic variants and a first-degree relative with pancreatic cancer [<a href="#rid100">100</a>]. There are no chemoprevention regimens or other prophylactic interventions that are known to benefit <em>CDKN2A</em> pathogenic variant carriers.</p><p>Patients with germline <em>BAP1</em> pathogenic variants should receive routine skin and ophthalmological examinations. Given the increased risk of mesothelioma and kidney cancer, a multidisciplinary team is often necessary to screen for <em>BAP1</em>-related visceral malignancies, although there are no formal evidence-based guidelines on how that should be done.</p><p>The prevalence of germline pathogenic variants in <em>CDK4</em>, the <em>TERT</em> promoter, and the shelterin complex is sufficiently low that there are no formal guidelines for management. Surveillance schedules should be similar to those for <em>CDKN2A</em> pathogenic variant carriers.</p><p>Familial clustering may be due to an inherited genetic risk or common environmental exposure with sporadic clustering. In either case, all family members are at risk and should obtain dermatologic screening and follow-up.</p><p class="headingAnchor" id="H3671659931"><span class="h2">Patients with melanoma</span><span class="headingEndMark"> — </span>For patients with diagnosed melanoma as well as a positive family history of melanoma, surveillance and follow-up should be guided by the patient's melanoma staging. (See  <a class="medical medical_review" href="/d/html/7620.html" rel="external">"Surgical management of primary cutaneous melanoma or melanoma at other unusual sites"</a>.)</p><p class="headingAnchor" id="H548176687"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – The chief environmental risk factor associated with cutaneous melanoma is exposure to ultraviolet (UV) radiation. This risk is modified by high-risk genetic factors, the most frequent of which are pathogenic variants in the <em>CDKN2A</em> tumor suppressor gene. Other genetic factors associated with an increased risk of melanoma have also been identified. (See  <a class="medical medical_review" href="/d/html/4844.html" rel="external">"Melanoma: Epidemiology and risk factors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>CDKN2A</em></strong> – Families with known germline <em>CDKN2A</em> pathogenic variants are characterized by having multiple family members with melanoma, early age of onset, individuals with multiple primary melanomas, and coexistence with other primary tumors, especially pancreatic cancer. However, even in the presence of these criteria, germline pathogenic variants in <em>CDKN2A</em> are uncommon. (See <a class="local">'CDKN2A gene'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other pathogenic variants</strong> – Pathogenic variants in several other genes have also been associated with a hereditary predisposition to melanoma (<em>CDK4</em>, <em>BAP1</em>, <em>MITF</em>, etc) and should be considered when evaluating patients. (See <a class="local">'CDK4 gene'</a> above and <a class="local">'BAP1 gene'</a> above and <a class="local">'MITF (E318K) variant'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic counseling</strong> – For patients thought to be at increased risk of having an inherited susceptibility to melanoma, we suggest genetic counseling with a qualified health care provider to receive education regarding the risks and benefits of genetic testing and to discuss disease expression and the associated changes to medical management (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Single-gene versus multigene panel'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance and management</strong> – For individuals with a pathogenic variant in a melanoma susceptibility gene, we recommend close clinical surveillance and education regarding melanoma risk-reducing behaviors (eg, sunscreen use, sun avoidance) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). (See <a class="local">'Surveillance and management'</a> above.)</p><p></p><p class="bulletIndent1">For individuals with <em>CDKN2A</em> or <em>CDK4</em> pathogenic variants, we also recommend consideration of referral to a gastroenterology specialist to discuss the option of pancreatic cancer surveillance for carriers who have a family history of pancreatic cancer in a relative known or suspected to carry the familial pathogenic variant. For patients with a <em>BAP1</em> pathogenic variant, referral to an ophthalmologist is reasonable. (See <a class="local">'Surveillance for other cancers'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient education on melanoma primary prevention and screening</strong> – For individuals thought to be at increased risk of having an inherited susceptibility to melanoma in whom no germline pathogenic variant is detected, we recommend education regarding melanoma risk-reducing behaviors and surveillance recommendations, which should be based upon the personal and family history (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See  <a class="medical medical_review" href="/d/html/4842.html" rel="external">"Primary prevention of melanoma"</a> and  <a class="medical medical_review" href="/d/html/4845.html" rel="external">"Screening for melanoma in adults and adolescents", section on 'High-risk patients'</a>.)</p><p></p><p class="headingAnchor" id="H2997205763"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michele Gabree, MS, CGC; Linda H Rodgers, MGC, CGC; and Devanshi Patel, MS, CGC, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Armstrong BK, English DR. Epidemiologic studies. In: Cutaneous Melanoma, Balch CM, Houghton AN, Milton GW, et al (Eds), JB Lippincott, Philadelphia 1992. p.12.</li><li class="breakAll">SEER Cancer Stat Facts: Melanoma of the Skin. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/statfacts/html/melan.html (Accessed on January 12, 2018).</li><li><a class="nounderline abstract_t">Mucci LA, Hjelmborg JB, Harris JR, et al. Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA 2016; 315:68.</a></li><li><a class="nounderline abstract_t">Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol 1998; 16:670.</a></li><li><a class="nounderline abstract_t">Rivers JK. Melanoma. Lancet 1996; 347:803.</a></li><li class="breakAll">Greene MH, Fraumeni JF, Jr. The hereditary variant of malignant melanoma. In: Human Malignant Melanoma, Clark WH, Jr, Goldman LI, Mastrangelo MJ (Eds), Grune Stratton, New York 1979. p.139.</li><li><a class="nounderline abstract_t">Gabree M, Patel D, Rodgers L. Clinical applications of melanoma genetics. Curr Treat Options Oncol 2014; 15:336.</a></li><li><a class="nounderline abstract_t">Leachman SA, Carucci J, Kohlmann W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 2009; 61:677.e1.</a></li><li><a class="nounderline abstract_t">Goldstein AM, Chan M, Harland M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006; 66:9818.</a></li><li><a class="nounderline abstract_t">Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007; 44:99.</a></li><li><a class="nounderline abstract_t">Leachman SA, Lucero OM, Sampson JE, et al. Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev 2017; 36:77.</a></li><li><a class="nounderline abstract_t">Haugh AM, Njauw CN, Bubley JA, et al. Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature. JAMA Dermatol 2017; 153:999.</a></li><li><a class="nounderline abstract_t">Fountain JW, Karayiorgou M, Ernstoff MS, et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A 1992; 89:10557.</a></li><li><a class="nounderline abstract_t">Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992; 258:1148.</a></li><li><a class="nounderline abstract_t">Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264:436.</a></li><li><a class="nounderline abstract_t">Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368:753.</a></li><li><a class="nounderline abstract_t">Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol 2000; 42:705.</a></li><li><a class="nounderline abstract_t">Binni F, Antigoni I, De Simone P, et al. Novel and recurrent p14 mutations in Italian familial melanoma. Clin Genet 2010; 77:581.</a></li><li><a class="nounderline abstract_t">Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704.</a></li><li><a class="nounderline abstract_t">Ohtani N, Zebedee Z, Huot TJ, et al. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 2001; 409:1067.</a></li><li><a class="nounderline abstract_t">Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994; 79:573.</a></li><li><a class="nounderline abstract_t">Sviderskaya EV, Hill SP, Evans-Whipp TJ, et al. p16(Ink4a) in melanocyte senescence and differentiation. J Natl Cancer Inst 2002; 94:446.</a></li><li><a class="nounderline abstract_t">Sviderskaya EV, Gray-Schopfer VC, Hill SP, et al. p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J Natl Cancer Inst 2003; 95:723.</a></li><li><a class="nounderline abstract_t">Begg CB, Orlow I, Hummer AJ, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005; 97:1507.</a></li><li><a class="nounderline abstract_t">Berwick M, Orlow I, Hummer AJ, et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev 2006; 15:1520.</a></li><li><a class="nounderline abstract_t">Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002; 94:894.</a></li><li><a class="nounderline abstract_t">Chaudru V, Chompret A, Bressac-de Paillerets B, et al. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 2004; 96:785.</a></li><li><a class="nounderline abstract_t">Soufir N, Avril MF, Chompret A, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998; 7:209.</a></li><li><a class="nounderline abstract_t">Goldstein AM, Struewing JP, Chidambaram A, et al. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000; 92:1006.</a></li><li><a class="nounderline abstract_t">Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996; 12:97.</a></li><li><a class="nounderline abstract_t">Puntervoll HE, Yang XR, Vetti HH, et al. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet 2013; 50:264.</a></li><li><a class="nounderline abstract_t">Aoude LG, Pritchard AL, Robles-Espinoza CD, et al. Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. J Natl Cancer Inst 2015; 107.</a></li><li><a class="nounderline abstract_t">Robles-Espinoza CD, Harland M, Ramsay AJ, et al. POT1 loss-of-function variants predispose to familial melanoma. Nat Genet 2014; 46:478.</a></li><li><a class="nounderline abstract_t">Speedy HE, Kinnersley B, Chubb D, et al. Germline mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia. Blood 2016.</a></li><li><a class="nounderline abstract_t">Bainbridge MN, Armstrong GN, Gramatges MM, et al. Germline mutations in shelterin complex genes are associated with familial glioma. J Natl Cancer Inst 2015; 107:384.</a></li><li><a class="nounderline abstract_t">Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013; 339:959.</a></li><li><a class="nounderline abstract_t">Harland M, Petljak M, Robles-Espinoza CD, et al. Germline TERT promoter mutations are rare in familial melanoma. Fam Cancer 2016; 15:139.</a></li><li><a class="nounderline abstract_t">Njauw CN, Kim I, Piris A, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 2012; 7:e35295.</a></li><li><a class="nounderline abstract_t">Pilarski R, Cebulla CM, Massengill JB, et al. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosomes Cancer 2014; 53:177.</a></li><li><a class="nounderline abstract_t">Aoude LG, Gartside M, Johansson P, et al. Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases. Twin Res Hum Genet 2015; 18:126.</a></li><li><a class="nounderline abstract_t">Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011; 43:1022.</a></li><li><a class="nounderline abstract_t">Popova T, Hebert L, Jacquemin V, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet 2013; 92:974.</a></li><li><a class="nounderline abstract_t">Carbone M, Yang H, Pass HI, et al. BAP1 and cancer. Nat Rev Cancer 2013; 13:153.</a></li><li><a class="nounderline abstract_t">Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet 2016; 89:285.</a></li><li><a class="nounderline abstract_t">Walpole S, Pritchard AL, Cebulla CM, et al. Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. J Natl Cancer Inst 2018; 110:1328.</a></li><li><a class="nounderline abstract_t">Yokoyama S, Woods SL, Boyle GM, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011; 480:99.</a></li><li><a class="nounderline abstract_t">Bertolotto C, Lesueur F, Giuliano S, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011; 480:94.</a></li><li><a class="nounderline abstract_t">Berwick M, MacArthur J, Orlow I, et al. MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors. Pigment Cell Melanoma Res 2014; 27:485.</a></li><li><a class="nounderline abstract_t">Ghiorzo P, Pastorino L, Queirolo P, et al. Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. Pigment Cell Melanoma Res 2013; 26:259.</a></li><li><a class="nounderline abstract_t">Potrony M, Puig-Butille JA, Aguilera P, et al. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations. JAMA Dermatol 2016; 152:405.</a></li><li><a class="nounderline abstract_t">Castro-Vega LJ, Kiando SR, Burnichon N, et al. The MITF, p.E318K Variant, as a Risk Factor for Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab 2016; 101:4764.</a></li><li><a class="nounderline abstract_t">Guhan SM, Artomov M, McCormick S, et al. Cancer risks associated with the germline MITF(E318K) variant. Sci Rep 2020; 10:17051.</a></li><li><a class="nounderline abstract_t">Valverde P, Healy E, Jackson I, et al. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995; 11:328.</a></li><li><a class="nounderline abstract_t">Landi MT, Kanetsky PA, Tsang S, et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 2005; 97:998.</a></li><li><a class="nounderline abstract_t">Valverde P, Healy E, Sikkink S, et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996; 5:1663.</a></li><li><a class="nounderline abstract_t">Palmer JS, Duffy DL, Box NF, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000; 66:176.</a></li><li><a class="nounderline abstract_t">Kennedy C, ter Huurne J, Berkhout M, et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001; 117:294.</a></li><li><a class="nounderline abstract_t">Box NF, Duffy DL, Chen W, et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001; 69:765.</a></li><li><a class="nounderline abstract_t">Fargnoli MC, Spica T, Sera F, et al. Re: MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 2006; 98:144.</a></li><li><a class="nounderline abstract_t">Scherer D, Nagore E, Bermejo JL, et al. Melanocortin receptor 1 variants and melanoma risk: a study of 2 European populations. Int J Cancer 2009; 125:1868.</a></li><li><a class="nounderline abstract_t">Demenais F, Mohamdi H, Chaudru V, et al. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst 2010; 102:1568.</a></li><li><a class="nounderline abstract_t">Haluska FG, Tsao H, Wu H, et al. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006; 12:2301s.</a></li><li><a class="nounderline abstract_t">Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135.</a></li><li><a class="nounderline abstract_t">Landi MT, Bauer J, Pfeiffer RM, et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 2006; 313:521.</a></li><li><a class="nounderline abstract_t">Fargnoli MC, Pike K, Pfeiffer RM, et al. MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol 2008; 128:2485.</a></li><li><a class="nounderline abstract_t">Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91:1310.</a></li><li><a class="nounderline abstract_t">Sinilnikova OM, Egan KM, Quinn JL, et al. Germline brca2 sequence variants in patients with ocular melanoma. Int J Cancer 1999; 82:325.</a></li><li><a class="nounderline abstract_t">Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 2015; 121:269.</a></li><li><a class="nounderline abstract_t">Kadouri L, Temper M, Grenader T, et al. Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin. Fam Cancer 2009; 8:29.</a></li><li><a class="nounderline abstract_t">Buecher B, Gauthier-Villars M, Desjardins L, et al. Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma. Fam Cancer 2010; 9:663.</a></li><li><a class="nounderline abstract_t">Curiel-Lewandrowski C, Speetzen LS, Cranmer L, et al. Multiple primary cutaneous melanomas in Li-Fraumeni syndrome. Arch Dermatol 2011; 147:248.</a></li><li><a class="nounderline abstract_t">Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012; 18:400.</a></li><li><a class="nounderline abstract_t">Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 2013; 50:255.</a></li><li><a class="nounderline abstract_t">Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993; 85:1121.</a></li><li><a class="nounderline abstract_t">Bartkova J, Lukas J, Guldberg P, et al. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996; 56:5475.</a></li><li><a class="nounderline abstract_t">Tsao H, Zhang X, Kwitkiwski K, et al. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol 2000; 136:1118.</a></li><li><a class="nounderline abstract_t">Berg P, Wennberg AM, Tuominen R, et al. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. Melanoma Res 2004; 14:251.</a></li><li><a class="nounderline abstract_t">Wang W, Niendorf KB, Patel D, et al. Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. Cancer Res 2010; 70:552.</a></li><li><a class="nounderline abstract_t">Blackwood MA, Holmes R, Synnestvedt M, et al. Multiple primary melanoma revisited. Cancer 2002; 94:2248.</a></li><li><a class="nounderline abstract_t">Monzon J, Liu L, Brill H, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998; 338:879.</a></li><li><a class="nounderline abstract_t">Auroy S, Avril MF, Chompret A, et al. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer 2001; 32:195.</a></li><li><a class="nounderline abstract_t">Puig S, Malvehy J, Badenas C, et al. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 2005; 23:3043.</a></li><li><a class="nounderline abstract_t">Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333:970.</a></li><li><a class="nounderline abstract_t">Vasen HF, Gruis NA, Frants RR, et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000; 87:809.</a></li><li><a class="nounderline abstract_t">Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995; 333:975.</a></li><li><a class="nounderline abstract_t">Potrony M, Puig-Butillé JA, Aguilera P, et al. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. J Am Acad Dermatol 2014; 71:888.</a></li><li><a class="nounderline abstract_t">Azizi E, Friedman J, Pavlotsky F, et al. Familial cutaneous malignant melanoma and tumors of the nervous system. A hereditary cancer syndrome. Cancer 1995; 76:1571.</a></li><li><a class="nounderline abstract_t">Randerson-Moor JA, Harland M, Williams S, et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 2001; 10:55.</a></li><li><a class="nounderline abstract_t">Harland M, Taylor CF, Chambers PA, et al. A mutation hotspot at the p14ARF splice site. Oncogene 2005; 24:4604.</a></li><li><a class="nounderline abstract_t">Walsh KM, de Smith AJ, Hansen HM, et al. A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution. Cancer Res 2015; 75:4884.</a></li><li><a class="nounderline abstract_t">Mandelker D, Zhang L, Kemel Y, et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA 2017; 318:825.</a></li><li><a class="nounderline abstract_t">de Snoo FA, Bergman W, Gruis NA. Familial melanoma: a complex disorder leading to controversy on DNA testing. Fam Cancer 2003; 2:109.</a></li><li><a class="nounderline abstract_t">Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999; 17:3245.</a></li><li><a class="nounderline abstract_t">Kasparian NA, Meiser B, Butow PN, et al. Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genet Med 2009; 11:265.</a></li><li><a class="nounderline abstract_t">Kasparian NA, Meiser B, Butow PN, et al. Better the devil you know? High-risk individuals' anticipated psychological responses to genetic testing for melanoma susceptibility. J Genet Couns 2006; 15:433.</a></li><li><a class="nounderline abstract_t">Aspinwall LG, Taber JM, Kohlmann W, et al. Unaffected family members report improvements in daily routine sun protection 2 years following melanoma genetic testing. Genet Med 2014; 16:846.</a></li><li><a class="nounderline abstract_t">Aspinwall LG, Leaf SL, Kohlmann W, et al. Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling. J Am Acad Dermatol 2009; 60:745.</a></li><li><a class="nounderline abstract_t">Loescher LJ, Crist JD, Siaki LA. Perceived intrafamily melanoma risk communication. Cancer Nurs 2009; 32:203.</a></li><li><a class="nounderline abstract_t">Taber JM, Aspinwall LG, Stump TK, et al. Genetic test reporting enhances understanding of risk information and acceptance of prevention recommendations compared to family history-based counseling alone. J Behav Med 2015; 38:740.</a></li><li><a class="nounderline abstract_t">Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62:339.</a></li></ol></div><div id="topicVersionRevision">Topic 7624 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Armstrong BK, English DR. Epidemiologic studies. In: Cutaneous Melanoma, Balch CM, Houghton AN, Milton GW, et al (Eds), JB Lippincott, Philadelphia 1992. p.12.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://seer.cancer.gov/statfacts/html/melan.html" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : SEER Cancer Stat Facts: Melanoma of the Skin. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/statfacts/html/melan.html (Accessed on January 12, 2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26746459" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Familial Risk and Heritability of Cancer Among Twins in Nordic Countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9469357" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Molecular genetics of familial cutaneous melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8622339" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8622339" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24652319" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical applications of melanoma genetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19751883" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Selection criteria for genetic assessment of patients with familial melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17047042" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16905682" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28283772" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Identification, genetic testing, and management of hereditary melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28793149" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1438246" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Homozygous deletions within human chromosome band 9p21 in melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1439824" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8153634" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A cell cycle regulator potentially involved in genesis of many tumor types.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8152487" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10775844" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20132244" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Novel and recurrent p14 mutations in Italian familial melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8259215" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11234019" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7954824" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904317" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : p16(Ink4a) in melanocyte senescence and differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12759390" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16234564" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16896043" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12072543" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Geographical variation in the penetrance of CDKN2A mutations for melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15150307" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9425228" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10861313" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8528263" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23384855" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25505254" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24686849" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : POT1 loss-of-function variants predispose to familial melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27528712" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Germline mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25482530" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Germline mutations in shelterin complex genes are associated with familial glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23348503" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : TERT promoter mutations in familial and sporadic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26433962" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Germline TERT promoter mutations are rare in familial melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22545102" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24243779" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25787093" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21874000" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Germline BAP1 mutations predispose to malignant mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23684012" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Germline BAP1 mutations predispose to renal cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23550303" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : BAP1 and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26096145" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30517737" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22080950" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22012259" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24406078" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23167872" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26650189" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27680874" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The MITF, p.E318K Variant, as a Risk Factor for Pheochromocytoma and Paraganglioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33051548" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cancer risks associated with the germline MITF(E318K) variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7581459" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15998953" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8894704" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10631149" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11511307" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11500805" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16418518" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Re: MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19585506" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Melanocortin receptor 1 variants and melanoma risk: a study of 2 European populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20876876" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16609049" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Genetic alterations in signaling pathways in melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16291983" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Distinct sets of genetic alterations in melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16809487" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : MC1R germline variants confer risk for BRAF-mutant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18368129" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : MC1R variants increase risk of melanomas harboring BRAF mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10433620" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cancer risks in BRCA2 mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10399947" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Germline brca2 sequence variants in patients with ocular melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25224030" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18679827" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20842456" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21339461" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Multiple primary cutaneous melanomas in Li-Fraumeni syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22252256" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Lifetime cancer risks in individuals with germline PTEN mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23335809" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8320741" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Mortality from second tumors among long-term survivors of retinoblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8968104" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10987867" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15305154" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20068151" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12001124" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Multiple primary melanoma revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9516223" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : CDKN2A mutations in multiple primary melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11579459" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15860862" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Role of the CDKN2A locus in patients with multiple primary melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7666916" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10956390" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7666917" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25064638" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8635060" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Familial cutaneous malignant melanoma and tumors of the nervous system. A hereditary cancer syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136714" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15856016" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A mutation hotspot at the p14ARF splice site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26527286" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28873162" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14574160" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Familial melanoma: a complex disorder leading to controversy on DNA testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10506626" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19265718" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17103321" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Better the devil you know? High-risk individuals' anticipated psychological responses to genetic testing for melanoma susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24763292" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Unaffected family members report improvements in daily routine sun protection 2 years following melanoma genetic testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19278751" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19295423" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Perceived intrafamily melanoma risk communication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26178773" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Genetic test reporting enhances understanding of risk information and acceptance of prevention recommendations compared to family history-based counseling alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23135763" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
